Safety and Efficacy of Long-term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial

Arthritis Rheumatol. 2023;76(1):59–67 DOI: 10.1002/art.42657

AURORA 2 demonstrated the safety and tolerability of continued administration of voclosporin over 3 years of treatment in patients with LN.

The aim of this study was to evaluate the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with LN receiving an additional 2 years of treatment following completion of the 1-year AURORA 1 study.

The data suggest that the rapid renal response achieved with voclosporin treatment has beneficial long-term consequences, supported by stable kidney function over the 3-year treatment period. Overall, 3-year data provides further support for the use of voclosporin with MMF and low-dose glucocorticoids for the treatment of LN.